Deep immune profiling of chronic rhinosinusitis in allergic and non-allergic cohorts using mass cytometry.
Allergy
Chronic rhinosinusitis
Cytokines
Mass cytometry
Peripheral blood mononuclear cells
Polyps
Journal
Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537
Informations de publication
Date de publication:
08 Mar 2024
08 Mar 2024
Historique:
received:
19
01
2024
revised:
19
02
2024
accepted:
20
02
2024
pubmed:
11
3
2024
medline:
11
3
2024
entrez:
10
3
2024
Statut:
aheadofprint
Résumé
Chronic rhinosinusitis (CRS) is a persistent nasal and paranasal sinus mucosa inflammation comprising two phenotypes, namely CRS with nasal polyps (CRSwNP) and without (CRSsNP). CRSwNP can be associated with asthma and hypersensitivity to non-steroidal anti-inflammatory drug (NSAID) in a syndrome known as NSAID-exacerbated respiratory disease (N-ERD). Furthermore, CRS frequently intertwines with respiratory allergies. This study investigated levels of 33 different nasal and serum cytokines and phenotypic characteristics of peripheral blood mononuclear cells (PBMCs) within cohorts of CRS patients (n = 24), additionally examining the influence of comorbid respiratory allergies by mass cytometry. N-ERD patients showed heightened type 2 nasal cytokine levels. Mass cytometry revealed increased activated naive B cell levels in CRSwNP and N-ERD, while resting naive B cells were higher in CRSsNP. Th2a cell levels were significantly elevated in allergic subjects, but not in CRS groups. In conclusion, there are distinct immunological features in PBMCs of CRS phenotypes and allergy.
Identifiants
pubmed: 38462155
pii: S1521-6616(24)00065-2
doi: 10.1016/j.clim.2024.110174
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
110174Informations de copyright
Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest SS served as a speaker and/or consultant and/or advisory board member for Sanofi, GSK, and Novartis. SS is an investigator for Novartis and AstraZeneca (grants paid to his institution). JED served as a speaker and/or consultant and/or advisory board member for Sanofi, Allergopharma, AstraZeneca, GSK, and Novartis. JED is an investigator for Novartis and AstraZeneca (grants paid to her institution).